COVID-19: Thrombosis, thromboinflammation, and anticoagulation considerations

Area of Science:

• Vascular biology
• Infectious diseases
• Immunology

Background:

• Vascular endothelial injury is a critical factor in acute infections, affecting both microvascular and macrovascular systems.
• Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, causing COVID-19, is characterized by hypercoagulability and thromboinflammation.
• The acute lung injury in COVID-19 stems from viral damage to vascular endothelium and resulting coagulopathy.

Purpose of the Study:

• To highlight the significance of vascular endothelial injury in COVID-19 pathophysiology.
• To emphasize the need for evaluating therapeutic interventions for thromboinflammatory responses.
• To inform clinical management strategies for current and future pandemics.

Main Methods:

• Review of current understanding of COVID-19 pathophysiology.
• Analysis of clinical sequelae related to vascular injury and coagulopathy.
• Mention of ongoing Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) studies.

Main Results:

• COVID-19 is associated with significant vascular endothelial damage and COVID-19-associated coagulopathy.
• Thromboinflammatory responses contribute to severe illness in critically ill patients.
• mRNA vaccines are being distributed to mitigate viral spread and associated injury.

Conclusions:

• Continued focus on vascular endothelial injury is essential for managing COVID-19.
• Therapeutic interventions targeting thromboinflammation may benefit patients with current and future infections.
• Vaccination holds promise for reducing the global impact of SARS-CoV-2 and related thromboinflammatory complications.